The National Comprehensive Cancer Network (NCCN) guideline for NSCLC (Version 1.2020) recommends targeted treatment for EGFR, ALK, ROS1, BRAF, NTRK, RET, HER2, MET amplification and exon 14 skipping mutation. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.